[1] 潘明, 陈闯, 牛志昊,等. 射频消融治疗甲状腺乳头状癌的临床进展[J]. 中国地方病防治杂志, 2015(3):182-183. [2] HAUGEN B R. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:What is new and what has changed?[J].Cancer,2017,123(3):372-381. [3] CHANG H, KIM SM, CHUN KW, et al.Clinicopathologic features of solid variant papillary thyroid cancer[J]. ANZ J Surg,2014,84(5):380-382. [4] KIM J H, YOO W S, PARK Y J, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm[J]. Radiology, 2015,276(3):909-918. [5] GARBEROGLIO R, ALIBERTI C, APPETECCHIA M, et al. Radiofrequency ablation for thyroid nodules:which indications? The first Italian opinion statement[J]. J Ultrasound, 2015, 18(4):423-430. [6] 周茂胜, 常欣. 射频消融原理及应用[J]. 当代医学, 2009, 15(21):18-19. [7] SHIN J E, BAEK J H, LEE J H. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers:Current status and challenges[J]. Current Opinion Oncol, 2012, 25(1):14-19. [8] FRANZ A M, SEITEL A, BOPP N, et al. First clinical use of the EchoTrack guidance approach for radiofrequency ablation of thyroid gland nodules[J]. Int J Computer Assisted Radiol Surg, 2017, 12(6):931-940. [9] 刘池拽, 邓建伟, 师天雄. RFA技术在甲状腺疾病中的临床进展[J]. 中华普通外科学文献:电子版, 2015(3):54-57. [10] XIAOYIN T, DAN C, JIACHANG C, et al. Evaluation of the safety and efficacy of radiofrequency ablation for treating benign thyroid nodules[J]. J Cancer, 2017, 8(5):754-760. [11] KIM J H, BAEK J H, SUNG J Y, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma:preliminary results for patients ineligible for surgery[J]. Int Hyperthermia, 2017, 33(2):8. [12] GUAN Y, LUO Y, ZHANG Y, et al. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma[J]. J Cancer Res Clin Oncol, 2017,143(8):1555-1562. [13] KIM C, LEE J H, CHOI Y J, et al. Complications encountered in ultrasonography-guided radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers[J]. Eur Radiol, 2017, 27(8):3128-3137. [14] 李建如, 罗渝昆, 李岩密,等. 超声引导下RFA治疗甲状腺微小乳头状癌的疗效分析[J]. 解放军医学院学报, 2016, 37(8):823-826. [15] 刘晓岭, 黄靖, 孙德胜,等. 超声引导下RFA治疗甲状腺微小乳头状癌的临床体会[J]. 黑龙江医学, 2015(1):69-70. [16] LONG B, LI L, YAO L, et al. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma[J]. J Cancer Res Therap, 2015, 11(Suppl 8):C244. [17] MONCHIK J M, DONATINI G, IANNUCCILLI J, et al. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma[J]. Ann Surg, 2006, 244(2):296-304. [18] XU D, CHEN L, QIAN C, et al. Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma[J]. J Cancer Res Therapeut, 2014, 10(7):144. [19] 张丹琦,赵滨滨,张素冰. 针刺复合舒芬太尼麻醉在微创甲状腺RFA术中的应用[A]. 中国中西医结合麻醉学会[CSIA]年会暨第二届全国中西医结合麻醉学术研讨会、江苏省中西医结合学会麻醉专业委员会成立大会论文汇编[C]. 扬州:2015. [20] ITO Y, MIYAUCHI A, KIHARA M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J]. Thyroid, 24(1):27-34. [21] JEONG S Y, BAEK J H, CHOI Y J, et al.Radiofrequency ablation of primary thyroid carcinoma:efficacy according to the types of thyroid carcinoma[J]. Int J Hyperthermia, 2018,34(5):611-616. [22] 董文武, 张浩, 张平,等. 甲状腺乳头状癌射频消融治疗后再手术5例临床分析[J]. 中国实用外科杂志, 2015, 35(6):653-655. [23] YANG L, TANG H, LEE A M, et al. Risk of malignancy in symptomatic nodular goiter treated with radiofrequency ablation[J]. AJNR Am Neuroradiol, 2015, 37(1):E7. [24] 田文, 王宇, 郗洪庆,等. 甲状腺疾病RFA治疗现状与争议[J]. 中国实用外科杂志, 2018,38(1):75-78. [25] LIM H K, BAEK J H, LEE J H, et al. Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer[J]. Eur Radiol, 2015, 25(1):163-170. [26] ZHAO Q, TIAN G, KONG D. Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers[J]. J Endocrinol Invest, 2016, 39(8):909-916. [27] MAZZEO S, CERVELLI R, ELISEI R, et al. mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation:a prospective study[J]. J Endocrinol Invest,2018,41(12):1389-1399. [28] 广旸, 罗渝昆, 张艳,等. 超声引导下RFA治疗PTC颈部转移淋巴结的疗效评价[J]. 中国医学科学院学报, 2018(1),40(1):67-71. [29] BAEK J H, NA D G, PARK H S. RE:Management of low-risk papillary thyroid microcarcinoma[J]. Korean J Radiol, 2017, 18(2):408-409. [30] CAZZATO R L, BONICHON F, BUY X, et al. Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer[J]. Eur J Surg Oncol,2015,41(9):1247-1255. [31] KIM M, KIM W G, PARK S, et al. Growth kinetics of macronodular lung metastases and survival in differentiated thyroid carcinoma[J]. Thyroid, 2017,27(7):915-922. [32] MASSICOTTE M H, BRASSARD M, CLAUDE-DESROCHES M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas:a retrospective study of the TUTHYREF network[J]. Eur J Endocrinol, 2014, 170(4):575-582. [33] 隋洋, 吴凤林, 孙医学. 超声引导下RFA甲状腺结节的并发症与预防方法探讨[J]. 医学影像学杂志, 2014, 24(1):32-35. [34] KIM J H, BAEK J H, SUNG J Y, et al. Radiofrequency ablation of low-risk small papillary thyroidcarcinoma:preliminary results for patients ineligible for surgery[J]. Int J Hyperthermia, 2017,33(2):212-219. [35] 娄雪峰, 吴凤林, 纪莉,等. RFA高风险甲状腺结节避免喉返神经损伤的方法探讨[J]. 中国超声医学杂志, 2014, 30(7):577-580. [36] BERNARDI S, LANZILOTTI V, PAPA G, et al.Full-thickness skin burn caused by radiofrequency ablation of a benign thyroid nodule[J]. Thyroid, 2016,26(1):183-184. [37] 马建新, 杜大勇, 李运田. 甲状腺功能减退患者RFA术后出现意识模糊一例[J]. 中国心脏起搏与心电生理杂志, 2009, 23(3):268-268. [38] ODDO S, SPINA B, VELLONE V G, et al. A case of thyroid cancer on the track of the radiofrequency electrode 30 months after percutaneous ablation[J]. J Endocrinol Invest, 2017,40(1):101-102. [39] LEE C U, KIM S J, SUNG J Y, et al. Needle track tumor seeding after radiofrequency ablation of a thyroid tumor[J]. Japan J Radiol, 2014, 32(11):661-663. |